UK markets closed

Xeris Pharmaceuticals, Inc. (XERS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.9800-0.0400 (-1.98%)
At close: 04:00PM EDT
1.9800 0.00 (0.00%)
After hours: 04:01PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-64,401
-62,255
-94,660
-122,725
-91,140
Depreciation & amortisation
13,193
13,160
12,668
1,879
1,467
Deferred income taxes
-942
-1,249
-1,424
0
-
Stock-based compensation
11,919
10,716
12,160
11,381
8,273
Change in working capital
1,931
-6,294
-35,150
11,854
-2,798
Accounts receivable
-6,554
-8,367
-13,374
-6,237
-2,182
Inventory
-13,319
-14,804
-7,465
-7,418
-5,143
Accounts payable
-4,447
6,959
-4,318
5,527
-2,486
Other working capital
-43,375
-49,286
-103,415
-96,620
-80,935
Other non-cash items
-4,978
-2,995
3,632
961
3,104
Net cash provided by operating activities
-41,186
-47,023
-102,891
-95,535
-80,558
Cash flows from investing activities
Investments in property, plant and equipment
-2,189
-2,263
-524
-1,085
-377
Purchases of investments
-24,486
-43,741
0
-43,020
-101,773
Sales/maturities of investments
45,000
40,000
34,985
103,600
74,745
Net cash used for investing activities
18,325
-6,004
34,461
97,964
-27,405
Cash flows from financing activities
Debt repayment
-11,831
0
-43,496
0
-25,089
Common stock issued
-
0
30,000
27,000
65,891
Common stock repurchased
-3,580
-1,009
-468
-534
-63
Other financing activities
-
-1,185
-5,613
-54
-10,318
Net cash used provided by (used for) financing activities
34,444
-1,613
127,473
27,247
126,064
Net change in cash
11,583
-54,640
59,043
29,673
18,079
Cash at beginning of period
55,332
126,314
67,271
37,598
19,519
Cash at end of period
66,915
71,674
126,314
67,271
37,598
Free cash flow
Operating cash flow
-41,186
-47,023
-102,891
-95,535
-80,558
Capital expenditure
-2,189
-2,263
-524
-1,085
-377
Free cash flow
-43,375
-49,286
-103,415
-96,620
-80,935